Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Double D Dairy
WARNING LETTER
•Double D Dairy•April 3, 2014

FDA WARNING_LETTER - Double D Dairy - April 03, 2014

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

On February 21, March 24, and April 3, 2014, the FDA investigated Double D Dairy, LLC, in Weidman, Michigan, and found violations of the Federal Food, Drug, and Cosmetic Act. The dairy adulterated new animal drugs Naxcel (ceftiofur sterile powder) and Vetrimycin 100 (oxytetracycline hydrochloride injection) by using them extralabelly, not as directed by approved labeling or a veterinarian's prescription.

Specifically, Naxcel was administered without following the approved duration of treatment, which is prohibited for extralabel use in cattle per 21 C.F.R. 530.41(a)(13). Vetrimycin 100 was administered to lactating dairy cows without following the approved route of administration, animal class, and duration of treatment, and this extralabel use was not under the supervision of a licensed veterinarian, violating 21 C.F.R. 530.11(a). These actions rendered the drugs unsafe under section 512(a) and adulterated under section 501(a)(5) of the FD&C Act.

The FDA acknowledged the dairy's April 14, 2014, response stating they would follow ceftiofur label directions and cease oxytetracycline use. The letter requires Double D Dairy to

Company
Double D Dairy
Inspection Date
April 3, 2014
Product Type
Drugs
Office
Detroit District Office
Person
  • Art O. Czabaniuk (Program Division Director)
Open in Dashboard

ID · 000999b0-d5ca-4525-8dc6-cf44b5d5507c

Violation Codes8
21 CFR 530.3(a)21 U.S.C. 360b(a)(4)21 U.S.C. 360b(a)(5)21 CFR 53021 CFR 530.41(a)(13)21 CFR 530.11(a)21 U.S.C. 360b(a)21 U.S.C. 351(a)(5)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.